Cytotoxic T-lymphocyte antigen-4 (CTLA-4) blockade via the monoclonal antibody ipilimumab also has attracted attention due to positive results in patients with metastatic melanoma and renal cell carcinoma, as well as several other malignancies [26]. Here, CTLA4 is linked to metastatic melanoma.